Aarti Drugs Sustainability Profile
Aarti Drugs Limited, commonly referred to as Aarti Drugs, is a prominent player in the pharmaceutical industry, headquartered in Mumbai, India. Established in 1984, the company has made significant strides in the production of active pharmaceutical ingredients (APIs) and formulations, catering to both domestic and international markets. With a diverse portfolio that includes anti-infectives, analgesics, and cardiovascular medications, Aarti Drugs stands out for its commitment to quality and innovation. The company has achieved several milestones, including regulatory approvals from major global health authorities, which solidify its market position. Recognised for its robust manufacturing capabilities and a strong emphasis on research and development, Aarti Drugs continues to contribute to the healthcare sector, ensuring the availability of essential medicines worldwide.
DitchCarbon Score
How does Aarti Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aarti Drugs's score of 27 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aarti Drugs's reported carbon emissions
In 2025, Aarti Drugs reported total carbon emissions of approximately 64,666,000 kg CO2e for Scope 1 and about 78,417,000 kg CO2e for Scope 2, resulting in a combined total of around 143,083,000 kg CO2e for both scopes. This data reflects their operations in India. In the previous year, 2024, the company recorded Scope 1 emissions of about 54,888,000 kg CO2e and Scope 2 emissions of approximately 78,220,000 kg CO2e, leading to a total of around 133,108,000 kg CO2e. Aarti Drugs has set ambitious climate commitments, aiming for a 50% reduction in both Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. This target underscores their commitment to sustainability and aligns with industry standards for greenhouse gas reduction. The company has not disclosed any Scope 3 emissions data, indicating a focus on direct and indirect emissions from their operations. Overall, Aarti Drugs is actively working towards significant emissions reductions while maintaining transparency in their climate impact reporting.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Scope 1 | 56,820,000 | 00,000,000 | 000,000,000 | - |
| Scope 2 | 76,414,000 | 00,000,000 | 00,000,000 | - |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Aarti Drugs's Industry?
How Carbon Intensive is Aarti Drugs's Location?
Aarti Drugs's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aarti Drugs has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
